These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 35397601)

  • 1. High ratio of pCXCR4/CXCR4 tumor infiltrating immune cells in primary high grade ovarian cancer is indicative for response to chemotherapy.
    Walther F; Berther JL; Lalos A; Ramser M; Eichelberger S; Mechera R; Soysal S; Muenst S; Posabella A; Güth U; Stadlmann S; Terracciano L; Droeser RA; Zeindler J; Singer G
    BMC Cancer; 2022 Apr; 22(1):376. PubMed ID: 35397601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphorylated CXCR4 expression has a positive prognostic impact in colorectal cancer.
    Weixler B; Renetseder F; Facile I; Tosti N; Cremonesi E; Tampakis A; Delko T; Eppenberger-Castori S; Tzankov A; Iezzi G; Kettelhack C; Soysal SD; von Holzen U; Spagnoli GC; Terracciano L; Tornillo L; Droeser RA; Däster S
    Cell Oncol (Dordr); 2017 Dec; 40(6):609-619. PubMed ID: 28936810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High density of CXCL12-positive immune cell infiltration predicts chemosensitivity and recurrence-free survival in ovarian carcinoma.
    Köhn P; Lalos A; Posabella A; Wilhelm A; Tampakis A; Caner E; Güth U; Stadlmann S; Spagnoli GC; Piscuoglio S; Richarz S; Delko T; Droeser RA; Singer G
    J Cancer Res Clin Oncol; 2023 Dec; 149(20):17943-17955. PubMed ID: 37966614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High OX40 expression in recurrent ovarian carcinoma is indicative for response to repeated chemotherapy.
    Ramser M; Eichelberger S; Däster S; Weixler B; Kraljević M; Mechera R; Tampakis A; Delko T; Güth U; Stadlmann S; Terracciano L; Droeser RA; Singer G
    BMC Cancer; 2018 Apr; 18(1):425. PubMed ID: 29661166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High density of CD66b in primary high-grade ovarian cancer independently predicts response to chemotherapy.
    Posabella A; Köhn P; Lalos A; Wilhelm A; Mechera R; Soysal S; Muenst S; Güth U; Stadlmann S; Terracciano L; Droeser RA; Zeindler J; Singer G
    J Cancer Res Clin Oncol; 2020 Jan; 146(1):127-136. PubMed ID: 31853662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue Expression and Prognostic Role of CXCL12 and CXCR4 in High-grade Serous Ovarian Carcinoma.
    Lim H; Kim SI; Kim EN; Lee M; Lee C; Kim JW; Chung HH
    Anticancer Res; 2023 Jul; 43(7):3331-3340. PubMed ID: 37351997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Density of CD16+ Tumor-Infiltrating Immune Cells in Recurrent Ovarian Cancer Is Associated with Enhanced Responsiveness to Chemotherapy and Prolonged Overall Survival.
    Lalos A; Neri O; Ercan C; Wilhelm A; Staubli S; Posabella A; Weixler B; Terracciano L; Piscuoglio S; Stadlmann S; Spagnoli GC; Droeser RA; Singer G
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Candidate prognostic biomarkers and prediction models for high-grade serous ovarian cancer from urinary proteomics.
    Ni M; Wan D; Wu J; Gong W; Wang J; Zheng Z
    J Proteomics; 2024 Jul; 304():105234. PubMed ID: 38925351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MPO density in primary cancer biopsies of ovarian carcinoma enhances the indicative value of IL-17 for chemosensitivity.
    Droeser RA; Mechera R; Däster S; Weixler B; Kraljević M; Delko T; Güth U; Stadlmann S; Terracciano L; Singer G
    BMC Cancer; 2016 Aug; 16():639. PubMed ID: 27531373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray.
    Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W
    Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer.
    Hillman RT; Chisholm GB; Lu KH; Futreal PA
    J Natl Cancer Inst; 2018 Mar; 110(3):265-72. PubMed ID: 29584920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High expression of fibroblast activation protein (FAP) predicts poor outcome in high-grade serous ovarian cancer.
    Li M; Cheng X; Rong R; Gao Y; Tang X; Chen Y
    BMC Cancer; 2020 Oct; 20(1):1032. PubMed ID: 33109151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High IL-17-positive tumor immune cell infiltration is indicative for chemosensitivity of ovarian carcinoma.
    Droeser RA; Güth U; Eppenberger-Castori S; Stadlmann S; Hirt C; Terracciano L; Singer G
    J Cancer Res Clin Oncol; 2013 Aug; 139(8):1295-302. PubMed ID: 23624523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrin Subunit beta 8 (ITGB8) Upregulation Is an Independent Predictor of Unfavorable Survival of High-Grade Serous Ovarian Carcinoma Patients.
    He J; Liu Y; Zhang L; Zhang H
    Med Sci Monit; 2018 Dec; 24():8933-8940. PubMed ID: 30531684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
    Petrillo M; Zannoni GF; Beltrame L; Martinelli E; DiFeo A; Paracchini L; Craparotta I; Mannarino L; Vizzielli G; Scambia G; D'Incalci M; Romualdi C; Marchini S
    Ann Oncol; 2016 Apr; 27(4):625-34. PubMed ID: 26782955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
    Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
    Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
    Ricciardelli C; Lokman NA; Pyragius CE; Ween MP; Macpherson AM; Ruszkiewicz A; Hoffmann P; Oehler MK
    Oncotarget; 2017 Mar; 8(11):17819-17832. PubMed ID: 28147318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting DUSP Activity as a Treatment for High-Grade Serous Ovarian Carcinoma.
    Sanders BE; Yamamoto TM; McMellen A; Woodruff ER; Berning A; Post MD; Bitler BG
    Mol Cancer Ther; 2022 Aug; 21(8):1285-1295. PubMed ID: 35587258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.